MetaVia (MTVA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
15 Apr, 2026Executive summary
The annual meeting will be held virtually on June 8, 2026, with voting on five key proposals, including director elections, auditor ratification, a reverse stock split, an equity plan amendment, and potential adjournment.
The Board unanimously recommends voting in favor of all proposals.
Only stockholders of record as of April 13, 2026, are entitled to vote, with each share representing one vote.
Forward-looking statements are included, subject to risks and uncertainties as detailed in the company's filings.
Voting matters and shareholder proposals
Proposal 1: Election of two Class I directors for three-year terms.
Proposal 2: Ratification of BDO USA, P.C. as independent auditor for 2026.
Proposal 3: Approval of a reverse stock split at a ratio between 1-for-5 and 1-for-22, at Board discretion.
Proposal 4: Amendment to the 2022 Equity Incentive Plan to add 200,000 shares.
Proposal 5: Authorization to adjourn the meeting if more votes are needed for Proposals 3 and 4.
Board of directors and corporate governance
The Board consists of seven members, with staggered three-year terms.
Six directors are independent under Nasdaq and SEC rules; the CEO is not independent.
Committees include audit, compensation, and nominating/corporate governance, each with defined charters and responsibilities.
Corporate governance guidelines, code of conduct, and insider trading policy are in place and available online.
Board and committee meetings are held regularly, with high attendance.
Latest events from MetaVia
- Q2 2026 net loss was $5.3M, R&D costs rose, and cash stood at $12.6M amid funding concerns.MTVA
Q2 2026 - Advancing next-gen obesity and MASH therapies with strong clinical data and near-term catalysts.MTVA
Investor presentation - Promising dual-action obesity and MASH therapies approach key data and partnership milestones.MTVA
Life Sciences Virtual Investor Forum - DA-1726 and vanoglipol show strong clinical and combination potential, with solid cash runway.MTVA
Emerging Growth Conference 93 - All five business proposals, including a reverse stock split, were approved by shareholders.MTVA
AGM 2026 - Strong clinical pipeline in obesity and MASH targets high-growth markets with near-term catalysts.MTVA
Investor presentation - Q1 2026 net loss was $3.8M; cash at $13.7M; clinical progress and going concern risk remain.MTVA
Q1 2026 - Annual meeting to vote on directors, auditor, reverse split, and equity plan amendment.MTVA
Proxy filing - Promising obesity and MASH therapies advance with strong early data and major market potential.MTVA
Investor presentation